-
Innovation Ranking
NewInnovation Ranking – Athersys Inc
Athersys Inc (Athersys) is a biotechnology company that discovers and develops novel and proprietary therapies in the field of regenerative medicine. It is investigating its lead platform, MultiStem, a patented stem cell product for treating chronic conditions such as cardiovascular diseases, inflammatory and immune disorders, neurological, and pulmonary disorders. The company’s MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, traumatic brain injury, vascular disease, acute pulmonary distress, wound healing, organ reperfusion, bone...
-
Company Insights
Innovation and Patenting activity of Athersys Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Athersys Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewNet Present Value Model: Geron Corp’s Imetelstat Sodium
Empower your strategies with our Net Present Value Model: Geron Corp's Imetelstat Sodium report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Feladilimab in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Feladilimab in Squamous Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AsiDNA in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AsiDNA in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AsiDNA in Epithelial Ovarian Cancer Drug Details: AsiDNA (DT-01) is...
-
Product Insights
Critical Limb Ischemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Critical Limb Ischemia - Drugs In Development, 2023’, provides an overview of the Critical Limb Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drugs In Development, 2023’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Occlusive Arterial Disease (OAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Occlusive Arterial Disease (OAD) - Drugs In Development, 2023’, provides an overview of the Occlusive Arterial Disease (OAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Drugs In Development, 2023’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Artery Occlusive Disease (PAOD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...